Vitiligo is an autoimmune condition in which your immune system destroys the cells that produce skin pigment, called melanocytes. The result is patches of skin that lose their color completely, appearing white or much lighter than the surrounding area. It affects roughly 0.1% to 1.2% of the population depending on region, and it can develop at any age, though it most commonly appears before 30.
How the Immune System Attacks Pigment Cells
Vitiligo starts with a case of mistaken identity. Your immune system, which normally targets viruses and bacteria, begins recognizing melanocytes as threats. The process involves multiple layers of immune response, but the final act of destruction is carried out by a specific type of white blood cell: CD8+ cytotoxic T cells. These cells lock onto melanocytes and kill them directly.
The attack is amplified by a chemical signaling loop. When CD8+ T cells reach the skin, they release a signaling molecule called IFN-gamma. This molecule does two things simultaneously. First, it’s directly toxic to melanocytes at high enough concentrations. Second, it triggers nearby skin cells to release chemical “beacons” that recruit even more CD8+ T cells to the area. This creates a self-reinforcing cycle: T cells arrive, release signals, and those signals pull in more T cells, expanding the area of pigment loss.
Other immune cells contribute too. Helper T cells skewed toward inflammatory responses flood the area with additional inflammatory signals. Another subset of immune cells, called Th17 cells, infiltrates affected skin and causes melanocyte death through a different mechanism involving damage to the cell’s energy-producing structures and a buildup of harmful molecules called reactive oxygen species. Meanwhile, regulatory T cells, which normally act as brakes on the immune system, don’t function properly in vitiligo, so nothing reins in the attack.
Why Patches Come Back in the Same Spots
One of the more frustrating features of vitiligo is its tendency to recur in previously affected areas, even after successful treatment. This happens because the immune system leaves behind sentinels. After the initial attack, a specialized group of memory T cells (called resident memory T cells) embed themselves in the skin. These cells remain at the site of previous patches and are primed for rapid cytotoxic responses, producing cell-killing proteins like perforin and granzyme B. They essentially keep the skin under permanent surveillance, ready to destroy any melanocytes that attempt to repopulate the area.
Genetics and What Triggers an Attack
Vitiligo has a strong genetic component, though it’s not caused by a single gene. One of the most well-studied genetic links involves a gene called HLA-A, part of the system your immune cells use to identify which proteins belong to your body and which don’t. A specific variant of this gene, HLA-A*02:01, is strongly associated with vitiligo risk. People who carry the high-risk version of this gene produce about 39% more of the HLA-A protein than people without it. That overproduction means their immune cells are more likely to present melanocyte proteins as targets, essentially making it easier for the immune system to “see” melanocytes as foreign.
Genetics loads the gun, but environmental factors often pull the trigger. Physical trauma to the skin can provoke new patches in a process called the Koebner phenomenon. The triggering injury can be mechanical (cuts, friction, burns), chemical (exposure to certain industrial compounds), thermal, or even from inflammatory skin conditions. Sunburn, emotional stress, and hormonal changes are also commonly reported triggers. Not everyone with genetic susceptibility develops vitiligo, and the specific combination of triggers that tips someone over the threshold varies from person to person.
Two Types With Different Behavior
Vitiligo comes in two major forms that behave quite differently.
Non-segmental vitiligo is the more common type. Patches tend to appear symmetrically on both sides of the body, often on the hands, face, and areas around body openings. It evolves over time, with patches gradually expanding and new ones appearing. Body hair in affected areas usually stays pigmented early on, though it can lose color as the disease progresses.
Segmental vitiligo follows a different pattern entirely. It affects only one side of the body, typically within a single segment of skin. It progresses rapidly, spreading within that segment over 6 to 24 months, and then stops. Further extension beyond that segment is rare. Segmental vitiligo also tends to affect hair follicles early, with up to 50% of patients developing white hair in the affected area. This distinction matters for treatment, because early hair involvement signals that the melanocyte stem cells in hair follicles (which play a key role in repigmentation) may already be compromised.
How Repigmentation Happens
When vitiligo patches do regain color, whether from treatment or spontaneously, the new pigment typically appears as small dots around hair follicles first. This pattern reveals something important about how the skin repairs itself. Melanocyte stem cells survive in a region of the hair follicle called the bulge, even in skin where all visible melanocytes have been destroyed. These stem cells are dormant and don’t produce pigment themselves.
In response to stimuli like UV light or wound healing, these stem cells divide and produce precursor cells called melanoblasts. The melanoblasts migrate out of the hair follicle, travel into the surrounding skin, multiply, and gradually mature into functioning melanocytes that begin producing pigment again. This is why treatments like phototherapy (which uses UV light) can stimulate repigmentation, and why areas with dense hair follicles, like the face, tend to respond better to treatment than areas with few follicles, like the fingertips and wrists.
How Treatments Break the Cycle
The discovery that vitiligo runs on a specific signaling loop has led to targeted treatments. The IFN-gamma signaling that recruits T cells to the skin depends on a cellular relay system called the JAK-STAT pathway. When IFN-gamma binds to a skin cell, it activates JAK enzymes inside the cell, which in turn activate STAT proteins that switch on genes producing the chemical beacons that attract more T cells. JAK inhibitors interrupt this relay. By blocking JAK enzymes, these medications break the recruitment loop, reducing the influx of destructive T cells and giving melanocyte stem cells an opportunity to repopulate the skin.
Topical JAK inhibitors applied directly to affected skin have shown effectiveness for non-segmental vitiligo, particularly on the face. The challenge remains that resident memory T cells persist in the skin even after treatment, which is why maintenance therapy is often needed to prevent relapse once repigmentation is achieved.
Linked Autoimmune Conditions
Because vitiligo reflects a broader tendency toward autoimmunity, it frequently co-occurs with other autoimmune conditions. The most common is thyroid disease, found in about 14% of adults with vitiligo, with hypothyroidism (including Hashimoto’s thyroiditis) accounting for roughly 10% and hyperthyroidism (including Graves’ disease) about 2%. Psoriasis appears in about 5% of vitiligo patients, and rheumatoid arthritis in about 3%.
Other associated conditions include alopecia areata (2.7%), type 1 diabetes (1.8%), pernicious anemia (1.7%), chronic hives (1.6%), and inflammatory bowel disease (1.4%). Less common associations include lupus, Sjögren’s syndrome, celiac disease, and Addison’s disease, all at roughly 1% or below. These overlaps suggest shared genetic pathways across autoimmune conditions, and they’re one reason screening for thyroid function is a standard part of vitiligo care.